PARP Inhibitors in Pancreatic Cancer
| Autor: | Timothy J, Brown, Kim A, Reiss |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Cancer J |
| ISSN: | 1540-336X 1528-9117 |
| DOI: | 10.1097/ppo.0000000000000554 |
| Popis: | Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second-leading cause of cancer-related death within the next ten years. Progress in the treatment of advanced pancreatic cancer has been slow. Systemic therapies rely on combination cytotoxic agents, with limited options at progression. Recently, poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors have demonstrated clinical activity in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2 and PALB2. In this review, we discuss the development of PARP inhibitors in pancreatic cancer, relevant clinical trials, and future directions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|